Skip to content

Study · Observational study · n = 69 · 2014

3 results

Multiple drug combination of anti-diabetic agents as a predictor for poor clinical response to liraglutide.

Haraguchi A, Fujishima K, Ando T, Mori F, Imaizumi M, Abiru N, Yamasaki H, Matsumoto K, Takamura N, Kawakami A

Minerva endocrinologica1 Dec 2014Cited by 4 (Europe PMC)

PMID25371055 (opens in a new tab)PepBankPUB-25371055
Publisher pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanObservational studyOther

    In adults with type 2 diabetes treated with liraglutide, a higher number of anti-diabetic agents was significantly associated with poor HbA1c response in multivariate analysis.

    In plain wordsIn adults with type 2 diabetes on liraglutide, taking more diabetes drugs was linked to a poorer HbA1c response.

    Peptide
    Liraglutide
    Outcome
    Not applicableNumber of anti-diabetic agents and poor response to liraglutide
    Study

    n = 69

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · longer than three monthsAs given in this study (human).

    Measurements

    P value
    0.02
    number of anti-diabetic agents

    Source sentences

    Summary
    Our analysis of the pretreatment clinical parameters revealed that number of anti-diabetic agents and use of sulfonylurea were significantly associated with poor response to liraglutide (P=0.02 and P=0.03, respectively) in a multivariate analysis.
    2 context sentences
    Summary · context
    We enrolled 106 patients with type 2 diabetes mellitus (T2DM), treated with liraglutide (N.=69) or exenatide (N.=37) for longer than three months.
    Summary · context
    Good responders were those whose HbA1c level had decreased by 1% or more, or maintained at less than 7%.
  2. 02HumanObservational studyOther

    In adults with type 2 diabetes treated with liraglutide, sulfonylurea use was significantly associated with poor HbA1c response in multivariate analysis.

    In plain wordsIn adults with type 2 diabetes on liraglutide, sulfonylurea use was linked to a poorer HbA1c response.

    Peptide
    Liraglutide
    Outcome
    Not applicableSulfonylurea use and poor response to liraglutide
    Study

    n = 69

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · longer than three monthsAs given in this study (human).

    Measurements

    P value
    0.03
    sulfonylurea use

    Source sentences

    Summary
    Our analysis of the pretreatment clinical parameters revealed that number of anti-diabetic agents and use of sulfonylurea were significantly associated with poor response to liraglutide (P=0.02 and P=0.03, respectively) in a multivariate analysis.
    2 context sentences
    Summary · context
    We enrolled 106 patients with type 2 diabetes mellitus (T2DM), treated with liraglutide (N.=69) or exenatide (N.=37) for longer than three months.
    Summary · context
    Good responders were those whose HbA1c level had decreased by 1% or more, or maintained at less than 7%.

Studies that did not test the peptide alone1

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 03HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In adults with type 2 diabetes treated with liraglutide or exenatide, approximately 35% were poor responders (pooled across both drugs).

    In plain wordsIn adults with type 2 diabetes on liraglutide or exenatide, about 35% responded poorly; the figure combines both drugs.

    Peptide
    Liraglutide
    Outcome
    Not applicableProportion of poor responders to GLP-1 analogues
    Study

    n = 106

    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    Poor responders
    ≈ 35%
    liraglutide and exenatide pooled

    Source sentences

    Summary
    Approximately 35% of the patients were poor responders.
    2 context sentences
    Summary · context
    We enrolled 106 patients with type 2 diabetes mellitus (T2DM), treated with liraglutide (N.=69) or exenatide (N.=37) for longer than three months.
    Summary · context
    Good responders were those whose HbA1c level had decreased by 1% or more, or maintained at less than 7%.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.